IRD Opus Genetics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why IRD matters now
Opus Genetics, Inc. (IRD) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.92 with -2.49% on the session and $323.7M in market capitalization; recent performance reads 1-month -4.46% and YTD +102.49%.
The latest financial table shown here is Q1 2026, with revenue of $2.2M, net income of $-65.5M, and EPS of $-0.75. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.6%.
The latest indexable market news headline is "Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $8.50; recent insider activity includes Foundation Fighting Blindness Retinal Degeneration Fund filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-77.16
P/S
28.04
EV/EBITDA
-2.88
DCF Value
$-0.31
FCF Yield
-11.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
49.6%
Operating Margin
-359.1%
Net Margin
-892.4%
ROE
6068.8%
ROA
-160.1%
ROIC
-74.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.2M | $-65.5M | $-0.75 |
| Q4 2025 | $3.9M | $-16.5M | $-0.19 |
| FY 2025 | $14.2M | $-49.6M | $-0.80 |
| Q3 2025 | $3.1M | $-17.5M | $-0.25 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$8.50
Target (Median)
$8.50
Target Range
$7.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.55
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.